|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Helicobacter pylori infection as a cause of iron deficiency anaemia of unknown origin显示文摘AIM: To assess the aetiological role of Helicobacter pylori (H. pylori) infection in adult patients with ironrefractory or iron-dependent anaemia of previously unknown origin. METHODS: Consecutive patients with chronic irondeficient anaemia (IDA) with H. pylori infection and a negative standard work-up were prospectively evaluated. All of them had either iron refractoriness or iron dependency. Response to H. pylori eradication was assessed at 6 and 12 mo from follow-up. H. pylori infection was considered to be the cause of the anaemia when a complete anaemia resolution without iron supplements was observed after eradication. RESULTS: H. pylori was eradicated in 88 of the 89 patients. In the non-eradicated patient the four eradicating regimens failed. There were violations of protocol in 4 patients, for whom it was not possible to ascertain the cause of the anaemia. Thus, 84 H. pylori eradicated patients (10 men; 74 women) were available to assess the effect of eradication on IDA. H. pylori infection was considered to be the aetiology of IDA in 32 patients (38.1%; 95%CI: 28.4%-48.8%). This was more frequent in men/postmenopausal women than in premenopausal women (75% vs 23.3%; P < 0.0001) with an OR of 9.8 (95%CI: 3.3-29.6). In these patients, anaemia resolution occurred in the first follow-up visit at 6 mo, and no anaemia or iron deficiency relapse was observed after a mean follow-up of 21 ± 2 mo. CONCLUSION: Gastric H. pylori infection is a frequent cause of iron-refractory or iron-dependent anaemia of previously unknown origin in adult patients. | Helena Monzón Montserrat Forné Maria Esteve Mercé Rosinach Carme Loras Jorge C Espinós Josep M Viver Antonio Salas Fernando Fernández-Baares | 2013 | World Journal of Gastroenterology2013，19，26： | 13 |
| 2 | A short review of malabsorption and anemia显示文摘Anemia is a frequent finding in most diseases which cause malabsorption. The most frequent etiology is the combination of iron and vitamin B12 deficiency. Celiac disease is frequently diagnosed in patients referred for evaluation of iron deficiency anemia (IDA), being reported in 1.8%-14.6% of patients. Therefore, duodenal biopsies should be taken during endoscopy if no obvious cause of iron defi ciency (ID) can be found. Cobalamin defi ciency occurs frequently among elderly patients, but it is often unrecognized because the clinical manifestations are subtle; it is caused primarily by food-cobalamin malabsorption and pernicious anemia. The classic treatment of cobalamin deficiency has been parenteral administration of the vitamin. Recent data suggest that alternative routes of cobalamin administration (oral and nasal) may be useful in some cases. Anemia is a frequent complication of gastrectomy, and has been often described after bariatric surgery. It has been shown that banding procedures which maintain digestive continuity with the antrum and duodenum are associated with low rates of ID. Helicobacter pylori (H pylori) infection may be considered as a risk factor for IDA, mainly in groups with high demands for iron, such as some children and adolescents. Further controlled trials are needed before making solid recommendations about H pylori eradication in these cases. | Fernando Fernández-Baares Helena Monzón Montserrat Forné | 2009 | World Journal of Gastroenterology2009，15，37： | 6 |
| 3 | Burden and outcomes for complex perianal fistulas in Crohn's disease:Systematic review显示文摘AIM To systematically review the literature on epidemiology,disease burden, and treatment outcomes for Crohn's disease(CD) patients with complex perianal fistulas.METHODS PubMed, Embase, and Cochrane were searched for relevant articles(published 2000-November 2016) and congress abstracts(published 2011-November 2016).RESULTS Of 535 records reviewed, 62 relevant sources were identified(mostly small observational studies). The cumulative incidence of complex perianal fistulas in CD from two referral-centre studies was 12%-14%(follow-up time, 12 years in one study; not reported in the second study). Complex perianal fistulas result in greatly diminished quality of life; up to 59% of patients are at risk of faecal incontinence. Treatments include combinations of medical and surgical interventions and expanded allogeneic adipose-derived stem cells. High proportions of patients experience lack of or inadequate response to treatment(failure and relapse rates,respectively: medical, 12%-73% and 0%-41%; surgical:0%-100% and 11%.20%; combined medical/surgical:0%-80% and 0%-50%; stem cells: 29%-47% and not reported). Few studies(1 of infliximab; 3 of surgical interventions)have been conducted in treatment-refractory patients, a population with high unmet needs. Limited data exist on the clinical value of anti-tumour necrosis factor-α dose escalation in patients with complex perianal fistulas in CD.CONCLUSION Complex perianal fistulas in CD pose substantial clinical and humanistic burden. There is a need for effective treatments, especially for patients refractory to antitumour necrosis factor-α agents, as evidenced by high failure and relapse rates. | Julian Panes Walter Reinisch Ewa Rupniewska Shahnaz Khan Joan Forns Javaria Mona Khalid Daniela Bojic Haridarshan Patel | 2018 | World Journal of Gastroenterology2018，24，42： | 5 |
| 4 | DNA methylation requires a DNMT1 ubiquitin interacting motif (UIM) and histone ubiquitination显示文摘 | Weihua Qin Patricia Wolf Nan Liu Stephanie Link Martha Smets Federica La Mastra Ignasi Forne Garwin Pichler David Horl Karin Fellinger Fabio Spada Ian Marc Bonapace Axel Imhof Hartmann Harz Heinrich Leonhardt | 2015 | Cell Research2015，25，8： | 5 |
| 5 | Aplastic anemia and severe pancytopenia during treatment with peg-interferon,ribavirin and telaprevir for chronic hepatitis C显示文摘Telaprevir and Boceprevir are the first direct acting antivirals approved for chronic hepatitis C in combination with peg-interferon alfa and ribavirin.Pancytopenia due to myelotoxicity caused by these drugs may occur,but severe hematological abnormalities or aplastic anemia(AA) have not been described.We collected all cases of severe pancytopenia observed during triple therapy with telaprevir in four Spanish centers since approval of the drug in 2011.Among 142 cirrhotic patients receiving treatment,7 cases of severe pancytopenia(5%) were identified and three were consistent with the diagnosis of AA.Mean age was 59 years,five patients had compensated cirrhosis and two patients had severe hepatitis C recurrence after liver transplantation.Severe pancytopenia was diagnosed a median of 10 wk after the initiation of therapy.Three patients had pre-treatment hematological abnormalities related to splenomegaly.In six patients,antiviral treatment was interrupted at the onset of hematological abnormalities.Two patients died due to septic complications and one patient due to acute alveolar hemorrhage.The remaining patients recovered.Severe pancytopenia and especially AA,are not rare during triple therapy with telaprevir in patients with advanced liver disease.Close monitoring is imperative in this setting to promptly detect serious hematological disorders and to prevent further complications. | Sabela Lens Jose L Calleja Ana Campillo Jose A Carrion Teresa Broquetas Christie Perello Juan de la Revilla Zoe Marino Maria-Carlota Londono Jose M Sanchez-Tapias Alvaro Urbano-Ispizua Xavier Forns | 2015 | World Journal of Gastroenterology2015，21，17： | 4 |
| 6 | 肝静脉压力梯度可鉴别肝移植后有丙肝复发高风险的患者显示文摘Liver biopsy is essential in the follow-up of HCV-infected liver transplant recipients.The aim of this study was to prospectively compare percutaneous(PLB)versus transjugular liver biopsy(TLB)in the assessment of liver damage.We also explored the diagnostic value of hepatic venous pressure gradient(HVPG)to identify patients at risk of severe HCV disease recurrence after liver transplantation(LT).One hundred and sixty paired PLB and TLB(with HVPG measurement)were performed 3 or 12 months after LT in 80 patients.Concordance for necroinflammation and fibrosis was fair or good,particularly 1 year after LT(kappa > or = 0.6).At this point,a significant positive association was seen between the median HVPG and the fibrosis stage(2.5 mm Hg for F0;5 mm Hg for F1,6 mm Hg for F2,and 11.5 mm Hg for F3;Kruscal-Wallis < 0.001).Despite this strong association,portal hypertension(HVPG > or = 6 mm Hg)was detected in 1(5%)of 22,4(16%)of 25,and 6(60%)of 10 patients with fibrosis stages 0,1,and 2,respectively.After a median follow-up of 38 months,clinical decompensation occurred in 15(19%)of 80 patients.Although the presence of significant fibrosis(F2-F3)1 year after transplantation was good to predict clinical decompensation(AUC:0.80),an HVPG of 6 mm Hg or greater was extremely accurate at identifying patients at risk of disease progression(AUC:0.96).In conclusion,HVPG determination is a valuable tool for follow-up in patients with HCV recurrence after LT. | Blasco A. Forns X. Carrión J.A. 陈云茹 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，9： | 3 |
| 7 | 由溶致液晶制备高强高模纤维素纤维显示文摘工业生产的三醋酯纤维素(分子量约 10~5)溶解在三氟乙酸(TFA)和二氯甲烷(CH_2CI_2)混合溶剂中,在一定浓度下可形成液晶。选择了不同条件进行液晶纺丝,再把初生纤维经过235℃热处理,通过不同皂化处理,得到强度为11.02cN/dtex,模量为 348.98cN/dtex的高强高模纤维素纤维。X-光衍射分析表明该纤维素纤维属于纤维素I族。 | 胡学超 Gilbert Fornes | 1996 | 中国纺织大学学报1996，22，1： | 3 |
| 8 | Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study显示文摘 | Michael P. Curry Xavier Forns Raymond T. Chung Norah A. Terrault Robert Brown Jonathan M. Fenkel Fredric Gordon Jacqueline O’Leary Alexander Kuo Thomas Schiano Gregory Everson Eugene Schiff Alex Befeler Edward Gane Sammy Saab John G. McHutchison G. Mani S | 2014 | Gastroenterology2014，，： | 3 |
| 9 | O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY显示文摘 | N. Afdhal G. Everson J.L. Calleja G. McCaughan W.T. Symonds J. Denning L. McNair J.G. McHutchison S. Arterburn M. Charlton R. Reddy T. Asselah E. Gane X. Forns | 2014 | Journal of Hepatology2014，，1： | 3 |
| 10 | ARFI, FibroScan?, ELF, and their combinations in the assessment of liver fibrosis: A prospective study显示文摘 | Gonzalo Crespo Guillermo Fernández-Varo Zoe Mari?o Gregori Casals Rosa Miquel Stella M. Martínez Rosa Gilabert Xavier Forns Wladimiro Jiménez Miquel Navasa | 2012 | Journal of Hepatology2012，，2： | 3 |
| 11 | Dead-time compensation for ABR traffic control over ATM networks显示文摘 | Gomez S F Fornes J M Rubio F R | 2002 | Control Engineering Practice2002，10，5： | 2 |
| 12 | Non-invasive evaluation of liver fibrosis using transient elastography显示文摘 | Laurent Castera Xavier Forns Alfredo Alberti | 2008 | Journal of Hepatology2008，，5： | 2 |
| 13 | Interferon-Free Regimens in the Liver-Transplant Setting显示文摘 | Sabela Lens Martina Gambato María-Carlota Londo?o Xavier Forns | 2014 | Semin Liver Dis2014，，01： | 2 |
| 14 | P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY显示文摘 | D. Samuel M. Charlton E. Gane R. Brown M. Curry P. Kwo R. Fontana R. Gilroy L. Teperman A.J. Muir J.G. McHutchison W.T. Symonds J. Denning L. McNair S. Arterburn N. Terrault X. Forns M. Manns | 2014 | Journal of Hepatology2014，，1： | 2 |
| 15 | Retransplantation in patients with hepatitis C recurrence after liver transplantation显示文摘 | José A. Carrión Miquel Navasa Xavier Forns | 2010 | Journal of Hepatology2010，，5： | 2 |
| 16 | An Interferon-free Antiviral Regimen for HCV after Liver Transplantation显示文摘 | Paul Y. Kwo Parvez S. Mantry Eoin Coakley Helen S. Te Hugo E. Vargas Robert Brown Fredric Gordon Josh Levitsky Norah A. Terrault James R. Burton Wangang Xie Carolyn Setze Prajakta Badri Tami Pilot-Matias Regis A. Vilchez Xavier Forns | 2014 | The New England Journal of Medicine2014，，25： | 2 |
| 17 | Nylon-6 Nano- composites from Alkylammonium-modified Clay: The Role of Alkyl Tails on Exfoliation 显示文摘 | FORNES T D HUNTER D L PAUL D R | 2004 | Macromolecules2004，37，5： | 1 |
| 18 | Non- invasive evalua- tion of liver fibrosis using transient elastography 显示文摘 | CASTERA L FORNS X ALBERTI A | 2008 | J Hepa- tol2008，48，5： | 1 |
| 19 | Polymer matrix degradation and color or formation in melt processed nylon6 /clay nanocomposites显示文摘 | Fornes T D Yoon P J Paul D R | 2003 | Polymer2003，44，24： | 1 |
| 20 | Rheological behavior of multiwalled carbon nanotube/polycarbonate composites显示文摘 | POETSCHLKE T FORNES T D PAUL D R | 2002 | Polymer2002，43，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员